| Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. | |
| | |
MedLine Citation:
|
PMID: 12538431 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Patients with chronic heart failure (CHF) are frequently anemic. An increase in hemoglobin could enhance exercise performance by increasing oxygen delivery. We investigated the effect of erythropoietin (EPO) on exercise performance in anemic patients with CHF. METHODS AND RESULTS: Twenty-six anemic patients aged 57+/-11 years were randomized to receive EPO (15 000 to 30 000 IU per week) or placebo for 3 months. Parameters measured at baseline and end therapy included blood parameters (hemoglobin, hematocrit, plasma volume), exercise parameters (peak oxygen consumption [VO2], exercise duration, 6-minute walk), muscle aerobic metabolism (half-time of VO2 and near infrared recovery), and forearm vasodilatory function. EPO was well tolerated by all patients. Twelve patients in the EPO group felt improvement versus 1 in the placebo group (P<0.05). There were significant increases in hemoglobin (11.0+/-0.5 to 14.3+/-1.0 g/dL, P<0.05), peak VO2 (11.0+/-1.8 to 12.7+/-2.8 mL. min(-1) x kg(-1), P<0.05) and exercise duration (590+/-107 to 657+/-119 s, P<0.004) in the EPO group but no significant changes in the control group. Resting and hyperemic forearm vascular resistance and indices of the rate of muscle oxidative capacity were unchanged in both groups. CONCLUSION: EPO significantly enhances exercise capacity in patients with CHF. One mechanism of improvement in VO2 is increased oxygen delivery from increased hemoglobin concentration. |
| | |
Authors:
|
Donna M Mancini; Stuart D Katz; Chim C Lang; John LaManca; Alhakam Hudaihed; Ana-Silvia Androne |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Circulation Volume: 107 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2003 Jan |
Date Detail:
|
Created Date: 2003-01-22 Completed Date: 2003-01-28 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 294-9 Citation Subset: AIM; IM |
Affiliation:
|
Department of Medicine, Columbia Presbyterian Medical Center, New York, NY, USA. dmm31@columbia.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anemia
/
complications,
drug therapy*,
physiopathology* Chronic Disease Erythrocyte Volume / drug effects Erythropoietin / therapeutic use* Exercise Test / drug effects Exercise Tolerance / drug effects* Female Forearm / blood supply, physiopathology Heart Failure / complications, physiopathology* Hemodynamics / drug effects Hemoglobins / analysis Humans Male Middle Aged Muscle, Skeletal / physiopathology Oxygen Consumption / drug effects Plasma Volume / drug effects Prospective Studies Quality of Life Single-Blind Method Treatment Outcome Vasodilation / drug effects |
| Grant Support | |
ID/Acronym/Agency:
|
5 M01 RR00645/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Hemoglobins; 11096-26-7/Erythropoietin |
| Comments/Corrections | |
Comment In:
|
Circulation. 2003 Aug 12;108(6):e41-2; author reply e41-2
[PMID:
12914016
]
Circulation. 2003 Jan 21;107(2):e9004 [PMID: 12538444 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving bet...
Next Document: Skeletal muscle reflex in heart failure patients: role of hydrogen.